Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
Xilio Therapeutics (Nasdaq: XLO) management will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xilio Therapeutics (Nasdaq: XLO) management will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m. ET. A live webcast will be available through “Events & Presentations” in the Investors & Media section at ir.xiliotx.com. A replay will remain available on the website for 30 days after the presentation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:40 p.m. ET.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
